PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering development of multi-functional novel immunotherapies, today announced that it has completed manufacturing of clinical batches of PDS0101 with its partner BSP Pharmaceuticals S.p.A, a leading manufacturer of anticancer drugs. The clinical batches of PDS0101 will be used in the Company’s two upcoming Phase 2 studies, which are expected to start in the first quarter of 2020. The trials include a combination study with Merck to evaluate PDS0101 in combination with KEYTRUDA® in first-line treatment of head and neck cancer and a study to evaluate PDS0101 in combination with two novel clinical-stage immunotherapies in advanced HPV associated cancers with the National Cancer Institute. “We are pleased to have completed the manufacturing of the clinical batches of PDS0101 with our partner BSP Pharmaceuticals and are honored to be collaboratin
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
PDSB
Earnings
- 11/14/24 - In-Line
PDSB
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/2/24 - Form 8-K
- PDSB's page on the SEC website